Cover Image

Tumor-associated neutrophils promote breast cancer progression via RLN2/RXFP1-C6orf99-STAT3 axis

Tumor-associated neutrophils (TANs) play a critical role in breast cancer progression. This study demonstrated that high CD66b+ TANs infiltration correlated with poor disease-free survival (DFS) and promoted proliferation, migration, and invasion of breast cancer cells in vitro. Conversely, the immu...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang, Shujing (Author) , Sheng, Youjing (Author) , Xu, Wuqin (Author) , Wang, Xian (Author) , Müller, Leon (Author) , Wu, Zhengsheng (Author) , Feng, Zhenzhong (Author) , Wu, Qiang (Author)
Format: Article (Journal)
Language:English
Published: 14 November 2025
In: International immunopharmacology
Year: 2025, Volume: 165, Pages: 1-15
ISSN:1878-1705
DOI:10.1016/j.intimp.2025.115478
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.intimp.2025.115478
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1567576925014699
Get full text
Author Notes:Shujing Wang, Youjing Sheng, Wuqin Xu, Xian Wang, Leon Müller, Zhengsheng Wu, Zhenzhong Feng, Qiang Wu
Description
Summary:Tumor-associated neutrophils (TANs) play a critical role in breast cancer progression. This study demonstrated that high CD66b+ TANs infiltration correlated with poor disease-free survival (DFS) and promoted proliferation, migration, and invasion of breast cancer cells in vitro. Conversely, the immune-related long non-coding RNA C6orf99 was downregulated in breast cancer and associated with favorable DFS. Functional assays revealed that C6orf99 suppressed tumor growth and metastasis by inhibiting STAT3 phosphorylation. Mechanistically, TANs-derived RLN2 downregulated C6orf99 through the RXFP1 receptor, thereby phosphorylating STAT3. Clinically, C6orf99 expression negatively correlated with TANs density and phospho-STAT3 levels in breast cancer tissues. These findings highlight the critical role of TANs in breast cancer progression through the regulation of C6orf99, offering potential therapeutic targets to disrupt the RLN2/RXFP1-C6orf99-STAT3 axis in breast cancer.
Item Description:Online verfügbar: 8. September 2025, Artikelversion: 8. September 2025
Gesehen am 17.11.2025
Physical Description:Online Resource
ISSN:1878-1705
DOI:10.1016/j.intimp.2025.115478

Similar Items